A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

• Autors principals: Vincenzo Raimondi (Autor), Nicolas Thomas Iannozzi (Autor), Jessica Burroughs-Garcìa (Autor), Denise Toscani (Autor), Paola Storti (Autor), Nicola Giuliani (Autor)
• Format: Llibre
• Publicat: Open Exploration Publishing Inc., 2022-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that is still uncurable. The therapies used to treat the disease target immune activity, inhibit proteasome...